Drug intelligence / Profile preview

BV-FA829

Development stage: Preclinical
Lead developer: BioViva
Modality: Gene Therapies
Administration: Parenteral

Overview

BV-FA829 is a preclinical gene therapy candidate being developed by BioViva. While specific details regarding its molecular target and mechanism of action are not publicly disclosed in the company's high-level pipeline documentation, BioViva focuses on developing gene therapies aimed at treating aging-related diseases and extending healthy human lifespan. The candidate is part of a broader portfolio of regenerative medicine assets targeting biological aging processes.

Targets

GDF8 (Myostatin)

Beyond the preview

Go deeper on BV-FA829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BV-FA829.

Explore the full profile